Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter ended March 31, 2025 (Q1 2025)
Business Overview: A clinical-stage life science company developing the proprietary formulation Gemini to rebalance inflammation. Key product candidates include GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), and GEM-PSI (post-surgical infection).
Corporate Action: A 1-for-16 reverse stock split was effected on January 28, 2025. All share data reflects this split.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,051,085) | $(2,681,433) |
| Net Loss Per Share (Basic/Diluted) | $(2.11) | $(39.37) |
| Operating Expenses | $2,094,987 | $1,902,138 |
| Cash and Cash Equivalents (End of Period) | $3,704,611 | $14,551,740 |
| Accumulated Deficit | $(42,556,723) | $(28,148,535) |
| Stockholders' Equity | $2,880,752 | $9,473,145 |
| Net Cash Used in Operating Activities | $(2,794,407) | $(2,837,969) |
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately $0.63 million compared to Q1 2024, primarily driven by a reduction in "Other (expense) income, net" which swung from a $0.78 million expense in 2024 to a $0.04 million income in 2025.
- Operating Expenses: Total operating expenses increased by $192,849 (10.1%).
- R&D: Increased by $141,248 due to higher clinical study expenses ($137k increase) and personnel costs ($69k increase).
- G&A: Increased by $51,601, driven by higher legal/professional fees and personnel expenses.
- Liquidity: Cash and cash equivalents declined by $2.8 million during the quarter, dropping from $6.5 million at year-end 2024 to $3.7 million at March 31, 2025.
- Capital Structure: Shares outstanding increased from 522,223 to 963,796, largely due to the alternative cashless exercise of 383,005 Class F Common Stock Warrants.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash reserves ($3.7 million) are not expected to sustain operations for one year from the filing date. Additional capital is required to continue development.
- Revenue Outlook: The company has never generated revenue and does not expect to do so for at least several years, if ever, pending regulatory approval.
- Financing Needs: The company plans to seek additional funding through public or private equity or debt financings. Failure to secure funding could force delays or elimination of R&D programs.
- Regulatory Risks: Significant risks include potential delays in FDA reviews due to workforce reductions and policy changes, which could impact clinical trial timelines and approval processes.
- Stock-Based Compensation: Stock-based compensation expense increased significantly to $223,455 in Q1 2025 (vs. $32,094 in Q1 2024), primarily due to Restricted Stock Awards (RSAs) granted to employees and directors.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and current burn rate of ~$2.8M per quarter.
- Dilution Risk: Review the terms of outstanding warrants (Classes C, D, E, F, G) and the impact of the recent cashless exercises on future dilution.
- Regulatory Timeline: Assess the impact of FDA staffing reductions on the specific clinical trials for GEM-AKI, GEM-CKD, and GEM-PSI.
- Expense Management: Monitor the trend in G&A expenses, which have risen alongside R&D, to ensure capital efficiency.
- Reverse Split Impact: Confirm the trading volume and liquidity of the stock post 1-for-16 reverse split.